We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App





STAGO sthemO and sthemE Product Ranges Make World Premiere

By LabMedica International staff writers
Posted on 24 May 2023

Diagnostica Stago (Asnières-sur-Seine, France) is unveiling its new coagulation line - the sthemO and sthemE product ranges - at WorldLab–EuroMedLab Roma 2023. More...

Leveraging its proficiency in hemostasis, Stago has diversified its product line to incorporate hematology, becoming a multi-specialist in these fields. The company's new "sthem" brand represents a significant leap towards next-generation Stago solutions. Drawing from over 60 years of partnership with coagulation professionals, Stago has introduced sthemO, a fresh line of hemostasis devices and reagents designed to fulfill the evolving demands of laboratories. The sthemO 301, the first analyzer in the sthemO hemostasis series, is a high-throughput, fully automated coagulation analyzer designed for medium to large laboratories and can be integrated into automated tracks. It offers the perfect combination of expertise, performance, and innovation. Also included in the new range of sthemO analyzers by Stago is the sthemO 201. This bench-top analyzer, suitable for smaller laboratories, offers the same level of efficiency and analytical performance as the sthemO 301. Its simplicity and versatility enable laboratories to concentrate on value-added tasks.

The sthemO analyzers are qualitative and/or quantitative automated hemostasis platforms for in vitro diagnostic use by clinical laboratory staff and are to be used with dedicated sthemO reagents and controls. The company has emphasized technological advancement, integrating an increasing number of features into its sthemO coagulation devices to simplify operations for laboratories and patients alike. The sthemO series incorporates immuno-chemiluminescence technology to provide superior analytical performance and an extensive range of tests. Additionally, Stago has developed a unique cuvette design, compatible with all embedded technologies, to provide a highly efficient, user-friendly system.

In order to optimize these two novel systems, Stago has also launched new eSolutions under the sthemE umbrella. The sthemE Manager is designed to facilitate data and information exchange between one or several in vitro diagnostic analyzers and laboratory information systems. This system, encompassing the sthemE Manager and one or more analyzers, is managed by authorized laboratory personnel. sthemE Manager is not intended for use with specific assays.

Related Links:
Diagnostica Stago


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.